Combination therapy of lower urinary tract disorders with a2d ligands and nsaids

A technique for urinary tract and ligands, which is applied in the field of pharmaceutical compositions comprising α2δ calcium channel subunit ligands and non-steroidal anti-inflammatory drugs, can solve problems such as difficult treatment of diseases

Inactive Publication Date: 2009-12-09
RECORDATI IRELAND LTD
View PDF41 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, while some advances have been made in the diagnosis, management, and treatment of lower urinary tract disorders, these disorders are often difficult to treat, according to the NIH

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy of lower urinary tract disorders with a2d ligands and nsaids
  • Combination therapy of lower urinary tract disorders with a2d ligands and nsaids
  • Combination therapy of lower urinary tract disorders with a2d ligands and nsaids

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0084] Solid unit dosage forms can be prepared by admixing the active agent of this invention with a pharmaceutically acceptable carrier and any other desired additives from those recited above. Typically, the mixture is mixed until a homogeneous mixture of the active drug of the invention and the carrier and any desired other additives is formed, ie, the active drug is uniformly and thoroughly dispersed throughout the composition. In this case, the composition may form dry or wet granules.

[0085] Tablets or pills may be coated, or may be presented in unit dosage form with delayed and / or sustained action, such as a controlled-release or delayed-release unit dosage form. For example, a tablet or pill may contain components of an inner dose and an outer dose, the latter may be in the form of a layer over the former or an envelope. The two components may be separated by an enteric layer, which serves to prevent disintegration in the stomach, to allow the inner component to ent...

Embodiment 1

[0136] Example 1: Bladder Pressure Examination in Anesthetized Rats Infused with Acetic Acid Bladder

[0137] Animal preparation: use Female rats (body weight 225-250 g) were anesthetized with urethane (1.25 g / kg s.c.), and a catheter (PE-50, 0.58 mm I.D. x 0.96 mm O.D.) was inserted into the jugular vein for intravenous administration. A midline subabdominal incision was made, a second PE-50 catheter was inserted into the bladder vault for bladder filling and pressure recording, and the incision was sutured.

[0138] Rats in each group were treated with NSAID alone (n=6-8) and gabapentin or pregabalin alone (n=6-8), and the cumulative dose-effect curve was obtained. Combinations (n=6-8) of different dose ratios of NSAID and gabapentin or pregabalin were determined as single non-cumulative administrations.

[0139] Drug Preparation and Administration Volume: Gabapentin, naproxen (sodium salt) and diclofenac (sodium salt) were dissolved in distilled water. Nimesulide, flu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The administration to a mammal of a combination of compounds, at least one of which is an a2d calcium channel subunit (A2d) ligand and at least one of which is a non-steroidal anti-inflammatory drug (NSAID), provides a surprising and potent inhibition of the micturition reflex, superior to that obtained by treatment with an A2d ligand or NSAID alone. Combinations of A2d ligand and NSAIDs are thus useful for treatment of lower urinary tract disorders and symptoms thereof. Preferred A2d ligands are gabapentin and pregabalin. Preferred NSAIDs are celecoxib, diclofenac, diflunisal, flurbiprofen, naproxen, nimesulide or sulindac.

Description

field of invention [0001] The present invention relates to alpha 2 Use of delta calcium channel subunit ligands and nonsteroidal anti-inflammatory drugs in combination therapy for lower urinary tract disorders involving the inclusion of alpha 2 A pharmaceutical composition of a delta calcium channel subunit ligand and a non-steroidal anti-inflammatory drug. Background of the invention [0002] Lower urinary tract disorders involve types of syndromes that affect normal urination. Lower urinary tract disorders may result from a combination of pathological and / or age-related changes in the genitourinary system or other etiologies, such as neurological disorders. Individuals with lower urinary tract disease have impaired quality of life, including distress, poor self-perception, and overall declines in emotional well-being, social skills, and health. Moreover, lower urinary tract disease may be associated with other physical conditions, including cellulitis, pressure ulcers, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61P13/10
CPCA61K45/06A61K31/197A61P13/00A61P13/02A61P13/10A61P43/00
Inventor A·莱奥纳蒂L·瓜尔内里P·安格利科
Owner RECORDATI IRELAND LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap